Benefit of Adjuvant Abemaciclib in High-Risk Early Breast Cancer Is Sustained at 5 YearsByColleen Bohnenkamp, PharmD, BCOP, BCPSDecember 22nd 2023The therapy sustained IDFS benefit compared with ET alone.